

- Imaging multiple myeloma:** Vij and colleagues provide a concise review of the present status and promising developments in multiple myeloma, including new molecular imaging biomarkers. **Page 1**
- EXINI quantitative BSI:** Larson offers perspective on an article in the current issue of *JNM* focusing on an improved and more accurate computerized bone scan index calculation that mimics but outperforms manual approaches. **Page 5**
- Coagulation factor and theranostics:** Urbain provides background for and previews an article in this issue of *JNM* on a novel approach for tagging, visualizing, and quantifying tissue factor expression at the surface of cancer cells using a radiolabeled agent. **Page 7**
- ⁶⁸Ga-BBN PET/CT in glioma:** Zhang and colleagues report on the safety, biodistribution, and radiation dosimetry of a gastrin-releasing peptide receptor–targeting, ⁶⁸Ga-labeled bombesin peptide–derivative PET tracer in healthy volunteers and assess receptor expression levels in glioma patients. **Page 9**
- Lung nodules missed by PET/MR:** Sawicki and colleagues report on a study evaluating outcomes in patients with small lung nodules missed by ¹⁸F-FDG PET/MR imaging and discuss the implications for clinical practice. **Page 15**
- PET/MR vs. PET/CT in NSCLC:** Huellner and colleagues compare the diagnostic accuracy of whole-body unenhanced PET/MR with that of PET/CT in TNM staging of non–small cell lung cancer. **Page 21**
- ⁶⁸Ga-HER2-nanobody PET/CT trial:** Keyaerts and colleagues describe phase 1 studies of the safety, biodistribution, dosimetry, and PET/CT tumor-targeting potential of a ⁶⁸Ga-labeled anti-human epidermal growth factor receptor 2 nanobody in women with primary or metastatic breast carcinoma. **Page 27**
- ⁶⁸Ga-DOTATATE PET in NETs:** Skoura and colleagues detail the results of the first 8 years of data from a large study of ⁶⁸Ga-DOTATATE PET/CT in neuroendocrine tumor management and the effect of imaging results on treatment and survival. **Page 34**
- Analytic validation of BSI:** Anand and colleagues report on a series of analytic validation studies to evaluate the performance of an automated bone scan index as a reproducible and quantitative imaging biomarker in patients with metastatic prostate cancer. **Page 41**
- ¹⁸F-DCFBC PET/CT in metastatic prostate cancer:** Rowe and colleagues examine the potential of this first-in-class radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen for detecting metastatic hormone-naïve and castration-resistant prostate cancer. **Page 46**
- Motion-corrected ¹⁸F-NaF PET:** Rubeaux and colleagues explore motion correction in gated ¹⁸F-NaF PET as a way to enhance image quality and improve uptake estimates in the assessment of vulnerable coronary artery plaques. **Page 54**
- Differential diagnosis of parkinsonism:** Tripathi and colleagues validate a probabilistic algorithm to classify subjects with clinical parkinsonism but uncertain diagnosis, based on expression of metabolic covariance patterns for idiopathic Parkinson disease, multiple-system atrophy, and progressive supranuclear palsy. **Page 60**
- ¹⁸F-FSPG PET in inflammation:** Chae and colleagues explore x_c⁻ transporter activity and the detection of inflammatory or infectious lesions with this L-glutamate–derivative PET agent that is specifically taken up by the x_c⁻ cysteine/glutamate system. **Page 67**
- Cohesive protocol for pediatric PET/MR:** Klenk and colleagues research the question of whether administration of gadolinium chelates is necessary for accurate characterization of pediatric tumors on ¹⁸F-FDG PET/MR images. **Page 70**
- PSF modeling in PET/MR:** Aklan and colleagues assess the quantitative and qualitative impact of inclusion of point-spread function modeling in the process of iterative PET image reconstruction in integrated PET/MR imaging. **Page 78**
- SUV_{peak} in lung cancer:** Laffon and colleagues compare average SUV_{peak} in a circumscribed volume in an ¹⁸F-FDG–positive lesion with an SUV computed from the 40 hottest voxels throughout the lesion to determine which identifies the most metabolically active areas. **Page 85**
- Quantitative PET TF imaging:** Nielsen and colleagues report on development of a novel PET tracer for specific imaging of tissue factor expression, which is upregulated in many solid tumors, using an ¹⁸F-labeled derivative of factor VII. **Page 89**
- PET/CT and CD30-positive lymphoma:** Rylova and colleagues describe the results of translational studies with ⁸⁹Zr-DFO-AC-10, a sensitive PET agent with high tumor-to-normal tissue contrast and promise for imaging in patients with lymphomas and other CD30-expressing diseases. **Page 96**
- ¹²⁴I PET and ¹³¹I SPECT detectability:** Beijst and colleagues investigate whether reported discrepancies between ¹²⁴I PET/CT and ¹³¹I SPECT/CT in ¹³¹I therapy may be ascribed to a difference in lesion detectability related to sufficient administered ¹²⁴I activity. **Page 103**
- PET imaging of copper trafficking:** Torres and colleagues describe brain copper trafficking in a transgenic mouse model of Alzheimer disease using PET imaging with ⁶⁴Cu, to determine its potential as a diagnostic biomarker of the disorder. **Page 109**
- ¹¹C-DASB and SERT imaging:** Walker and colleagues assess the feasibility of using ¹¹C-DASB, a serotonin transporter ligand, for reproducible quantification of serotonin transporter density and affinity in vivo in rats and mice. **Page 115**
- Uncertainty and absorbed dose:** Spielmann and colleagues detail the development of an uncertainty analysis method and its use in calculating uncertainty in internal doses of 7 common radiopharmaceuticals. **Page 122**
- Troglitazone and cancer cell glycolysis:** Moon and colleagues evaluate the way in which troglitazone influences cancer cell glucose metabolism and uptake of ¹⁸F-FDG and investigate its molecular mechanism in relation to anticancer effects. **Page 129**
- MR-based pseudo-CT synthesis for PET/MR:** Torrado-Carvajal and colleagues describe a methodology for synthesizing a pseudo-CT volume from a single T1-weighted volume, facilitating creation of attenuation correction maps for PET/MR. **Page 136**
- Consensus report on fluorescence guidance:** Rosenthal and authors from the International Society of Image Guided Surgery critically evaluate imaging technology and agents for fluorescence-guided oncologic surgery and make recommendations for clinical trial development. **Page 144**
- EANM/MIRD Pamphlet 26:** Ljungberg and colleagues from the SNMMI Medical Internal Radiation Dose Committee and the European Association of Nuclear Medicine present the latest in a series of isotope-specific guidelines, here focusing on ¹⁷⁷Lu and applications in radiopharmaceutical therapy. **Page 151**